Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Damora Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
19.7
24.6
38.5
48.2
23.8
6.4
26.9
General and administrative
2.45
9.01
13.7
13
12.7
10.5
9.69
Operating expenses
39
33.6
52.2
61.2
39.9
22.3
211
Operating income
39
-33.6
-52.2
-61.2
-39.9
-22.3
-211
Other non-operating income
2.46
-1.2
0.48
-0.42
1.56
0.86
1.08
Pre-tax income
-36.5
-34.8
-51.8
-61.6
-38.3
-21.4
-210
Income tax
0
0
0
0
0
0.04
0.05
Net income
-36.5
-34.8
-51.8
-61.6
-38.3
-21.4
-210
EBITDA
-52.2
-61.2
-39.6
-22.2
-211
EPS, basic
-4,054.00
-190.92
-51.36
-60.89
-36.08
-18.53
3.98
EPS, diluted
-4,054.00
-190.92
-51.36
-60.89
-36.08
-18.53
3.98
Shares, basic (weighted)
0.01
0.18
1.01
1.01
1.06
1.16
1.36
Shares, diluted (weighted)
0.01
0.18
1.01
1.01
1.06
1.16
1.36
Dividend per share
0.00
0.00
0.00
0.00
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
11.3
164
62.6
32.8
21.5
14.2
258
Short-term investments
37.6
27.4
11.7
Other current assets
5.12
5.71
9.91
3.69
3.62
2.66
2.8
Total current assets
56.1
169
110
63.9
36.8
16.8
260
Property, plant and equipment
0.2
0.36
0.08
0.06
0.04
Lease right-of-use assets
0.3
0.89
0.83
0.81
0.25
0.07
0.07
Long-term investments
9.05
5.83
Other non-current assets
1.16
2.03
2.28
1.13
0.16
0.1
Total assets
56.6
172
122
73.2
38.2
17.1
261
Accounts payable
3.33
2.85
1.53
3.35
1.7
0.38
0.44
Accrued liabilities
4.6
2.72
3.01
7.76
4.13
0.82
2.4
Total current liabilities
7.93
5.57
4.54
11.1
5.83
1.2
20.1
Lease liabilities
0.21
0.54
0.45
0.33
0.07
0.06
0.05
Other non-current liabilities
0.04
0.08
Total liabilities
8.14
6.11
4.99
11.4
5.9
1.3
20.1
Paid-in capital
0.83
269
274
280
288
292
311
Retained earnings
-69.5
-104
-156
-218
-256
-278
-487
Other comprehensive income
-2.45
0.67
-0.32
-0.24
0.38
0.1
0.8
Shareholders' equity
-71.1
165
117
61.8
32.3
15.8
240
Total equity
-71.1
165
117
61.8
32.3
15.8
240
Total liabilities and equity
56.6
172
122
73.2
38.2
17.1
261
Shares outstanding
0.01
1.01
1.01
1.02
1.08
1.32
1.6
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-36.5
-34.8
-51.8
-61.6
-38.3
-21.4
-210
Depreciation and amortization
0.02
0.04
0.27
0.02
0.02
Stock-based compensation
0.98
4.48
5.57
5.43
3.24
1
Change in payables
1.94
-0.48
-1.32
1.82
-1.65
-1.33
0.05
Cash from operations
-19.3
-38.2
-52.3
-42.9
-36.9
-18.6
-6.73
Capital expenditures
-0.22
-0.2
Acquisitions
-0.33
-17.4
Purchases of investments
-84.2
-44.9
-25.9
Sales and maturities of investments
36.4
57.4
48.2
11.7
Cash from investing
-0.33
-48
12.4
22.3
11.7
-17.4
Stock issued
0
0.51
2.88
Cash from financing
187
0.51
2.88
267
Exchange rate effect
0.05
3.13
-0.92
0.26
0.38
-0.32
0.71
Net change in cash
-19.7
149
-100
-30
-11.7
-6.97
243
Free cash flow
-52.5
-43.1
Income taxes paid
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $20.66 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-50.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-48.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
1,418.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
57.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
7.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1,421.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
52.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
8.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
17.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
10.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
49.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
19.7x
Current assets / current liabilities.
Quick ratio
19.6x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
19.6x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.73
Cash from operations / diluted weighted shares.
Book value per share
$8.36
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
2.47x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.47x
Market cap / tangible book value, when positive.
Earnings yield
-20.6%
Net income / market cap (the inverse of P/E).
Was Damora Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $209.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.